ATE466031T1 - Anti-hgf-r-antikörper und deren verwendung - Google Patents

Anti-hgf-r-antikörper und deren verwendung

Info

Publication number
ATE466031T1
ATE466031T1 AT04741691T AT04741691T ATE466031T1 AT E466031 T1 ATE466031 T1 AT E466031T1 AT 04741691 T AT04741691 T AT 04741691T AT 04741691 T AT04741691 T AT 04741691T AT E466031 T1 ATE466031 T1 AT E466031T1
Authority
AT
Austria
Prior art keywords
antibodies
hgf
relates
hfg
secretes
Prior art date
Application number
AT04741691T
Other languages
English (en)
Inventor
Maria Giovanna Prat
Original Assignee
Uni Degli Studi Del Piemonte O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Del Piemonte O filed Critical Uni Degli Studi Del Piemonte O
Application granted granted Critical
Publication of ATE466031T1 publication Critical patent/ATE466031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04741691T 2003-06-05 2004-06-01 Anti-hgf-r-antikörper und deren verwendung ATE466031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001127A ITMI20031127A1 (it) 2003-06-05 2003-06-05 Anticorpi anti-hgf-r e loro uso
PCT/EP2004/050976 WO2004108766A2 (en) 2003-06-05 2004-06-01 Anti-hgf-r antibodies and their use

Publications (1)

Publication Number Publication Date
ATE466031T1 true ATE466031T1 (de) 2010-05-15

Family

ID=30131145

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741691T ATE466031T1 (de) 2003-06-05 2004-06-01 Anti-hgf-r-antikörper und deren verwendung

Country Status (8)

Country Link
US (1) US7556804B2 (de)
EP (1) EP1641828B1 (de)
AT (1) ATE466031T1 (de)
CA (1) CA2524329A1 (de)
DE (1) DE602004026872D1 (de)
DK (1) DK1641828T3 (de)
IT (1) ITMI20031127A1 (de)
WO (1) WO2004108766A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
KR20110126748A (ko) 2009-04-07 2011-11-23 로슈 글리카트 아게 이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
ITTO20091020A1 (it) * 2009-12-21 2011-06-22 Uni Degli Studi Del Piemonte Orientale Ame "cardiomyocytes anti-apoptotic molecules, products and compositions thereof"
ES2993335T3 (en) 2010-03-10 2024-12-27 Genmab As Monoclonal antibodies against c-met
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
WO2018014111A1 (en) 2016-06-22 2018-01-25 Harless William Warren Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neul sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0584125T3 (da) 1991-05-10 1997-09-08 Pharmacia & Upjohn Spa Afkortede former af hepatocyt vækstfaktor (HGF) receptor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト

Also Published As

Publication number Publication date
ITMI20031127A1 (it) 2004-12-06
DK1641828T3 (da) 2010-08-02
EP1641828A2 (de) 2006-04-05
CA2524329A1 (en) 2004-12-16
DE602004026872D1 (de) 2010-06-10
WO2004108766A3 (en) 2005-06-30
EP1641828B1 (de) 2010-04-28
US7556804B2 (en) 2009-07-07
US20060140940A1 (en) 2006-06-29
WO2004108766A2 (en) 2004-12-16
ITMI20031127A0 (it) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE466031T1 (de) Anti-hgf-r-antikörper und deren verwendung
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
ATE495248T1 (de) Monoklonaler anti-cd20-antikörper
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
DE602007013282D1 (de) Monoklonale antikörper gegen den humanen anti-müllerian-hormonrezeptor vom typ ii (amhr-ii)
MY147019A (en) Anti-alpha v beta 6 antibodies
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
CR9562A (es) Anticuerpos anti-cd40 humanizados y sus metodos de uso
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
WO2006084092A3 (en) Antibodies to oncostatin m receptor
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
DK1519748T3 (da) Mikropartikler med CD28-specifikke monoklonale antistoffer
EP4223778A4 (de) Anti-claudin18.2- und cd3-bispezifischer antikörper und verwendung davon
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
EP4421092A4 (de) Bispezifischer anti-cd47-cldn18.2-antikörper und verwendung davon
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
EP4578873A4 (de) Monoklonaler antikörper gegen den menschlichen interleukin-36-rezeptor und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1641828

Country of ref document: EP